Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983658 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL8187613 | 0.81 | — | — | |
| SCHEMBL2389905 | 0.79 | DRD2 (0.43) | TSHRHSD17B10DRD2DRD3 | |
| SCHEMBL5161870 | 0.78 | TSHR (0.33) | TSHRHSD17B10CYP2A6KDM4EL3MBTL1 | |
| SCHEMBL15648671 | 0.77 | BDKRB2 (0.36) | TSHRHSD17B10ALDH1A1CYP19A1KDM4E | |
| SCHEMBL15648819 | 0.77 | BDKRB2 (0.36) | TSHRHSD17B10ALDH1A1CYP19A1KDM4E | |
| SCHEMBL1452840 | 0.75 | HTT (0.38) | TSHRALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL6785580 | 0.74 | CYP2A6 (0.52) | TSHRHSD17B10CYP2A6ALDH1A1MGLL | |
| SCHEMBL7012232 | 0.74 | TSHR (0.36) | TSHRALDH1A1HPGD | |
| SCHEMBL2429966 | 0.74 | KDM4E (0.46) | TSHRHSD17B10CYP2A6ALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117674-A1 | MICROFLUIDIC REACTOR FOR CONTROLLING CHEMICAL REACTION AND CHEMICAL REACTION CONTROL METHOD USING THE SAME | POSTECH Research and Business Development Foundation (KR) | 2023-04-20 | — | — | US | disclosed |
| CN-108864173-B | Process for converting substituted sodium arylsulfinates into aryltri-n-butyltin | 天津师范大学 | 2020-07-21 | — | — | CN | disclosed |
| US-9163046-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9024093-B2 | Fluorination of organic compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-12-22 | — | — | US | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
| EP-0745089-B1 | ANTIPARASITIC AGENTS | PFIZER LTD (GB) | 1998-12-09 | — | — | EP | disclosed |
| US-5723488-A | Antiparasitic agents | PFIZER INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5609848-A | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0745089-A1 | ANTIPARASITIC AGENTS | Pfizer Limited (GB) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995022552-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 1995-08-24 | — | — | WO | disclosed |
| US-5213787-A | RADIOHALOGENATED SMALL MOLECULES FOR PROTEIN LABELING | NEORX CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| US-5045303-A | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1991-09-03 | — | — | US | disclosed |
| US-4885153-A | Radiohalogenated for proteins | NEORX CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0203764-A2 | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | SLCO1B3, SLCO2B1, FLI1 | TSHR 2588/4885HSD17B10 1490/4885CYP2A6 434/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | TSHR 2037/4885HSD17B10 2096/4885CYP2A6 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.